Type III interferons exhibit antiviral activity against influenza viruses, coronaviruses, rotaviruses, and others. In addition, this type of interferon theoretically has therapeutic advantages, in comparison with type I interferons, due to its ability to activate a narrower group of genes in a relatively small group of target cells. Hence, it can elicit more targeted antiviral or immunomodulatory responses. Obtaining biologically-active interferon lambda (hIFN-λ₁) is fraught with difficulties at the stage of expression in soluble form or, in the case of expression in the form of inclusion bodies, at the stage of refolding. In this work, hIFN-λ₁ was expressed in the form of inclusion bodies, and a simple, effective refolding method was developed. Efficient and scalable methods for chromatographic purification of recombinant hIFN-λ₁ were also developed. High-yield, high-purity product was obtained through optimization of several processes including: recombinant protein expression; metal affinity chromatography; cation exchange chromatography; and an intermediate protein refolding stage. The obtained protein was shown to feature expected specific biological activity in line with published effects: induction of MxA gene expression in A549 cells and antiviral activity against influenza A virus.

III 型干扰素对流感病毒、冠状病毒、轮状病毒等表现出抗病毒活性。此外，与 I 型干扰素相比，这种类型的干扰素在理论上具有治疗优势，因为它能够在相对较小的靶细胞群中激活较窄的一组基因。因此，它可以引发更有针对性的抗病毒或免疫调节反应。获得具有生物活性的干扰素 λ (hIFN-λ ₁ ) 在以可溶形式表达的阶段，或者在以包涵体形式表达的情况下，在重折叠阶段充满困难。在这项工作中，hIFN-λ ₁以包涵体的形式表达，并开发了一种简单、有效的复性方法。还开发了用于重组 hIFN-λ ₁的色谱纯化的高效且可扩展的方法。通过重组蛋白表达、重组蛋白表达等工艺优化，获得高产、高纯度的产品。金属亲和层析；阳离子交换层析；和一个中间蛋白重折叠阶段。所获得的蛋白质显示出与已发表的效果一致的预期特定生物活性：在 A549 细胞中诱导 MxA 基因表达和抗甲型流感病毒的抗病毒活性。